Advances in the Treatment of Blood Cancers

January 12, 2017

Michael E. Williams, MD, ScM, of the University of Virginia in Charlottesville, recently attended the American Society of Hematology Annual Meeting, held in San Diego. “It's a very dynamic time in lymphoma treatment,” reports Dr. Williams, who is the Cancer.Net Associate Editor for lymphoma.

In this podcast, he discusses some of the major research presented at last month’s meeting. share on twitter Highlights include research on:

  • The use of obinutuzumab (Gazyva), rather than rituximab (Rituxan), plus chemotherapy for patients with advanced-stage follicular lymphoma [2:13].

  • Possible alternate regimens to the standard treatment regimen using rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for patients with diffuse large B-cell lymphoma [3:51].

  • The use of rituximab to prolong remission in patients treated for mantle cell lymphoma with autologous (AUTO) stem cell transplantation [6:16].

  • A new immunotherapy approach using chimeric antigen receptor (CAR) T cells for patients with aggressive lymphomas [9:30].

This is a prerecorded audio podcast. It can be listened to online or downloaded (mp3) to your computer. A transcript of this podcast is also available. For more information, visit the Cancer.Net podcast page.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.